Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

Inclusion Criteria:

• 18-75 years old
• Diagnosed with B-NHL
• Relapsed after or be refractory to at least 2 line of standard therapy

Exclusion Criteria:

• Active central nervous system (CNS) metastases
• Positive Direct Antiglobulin Test (DAT)
• Active autoimmune disorder
• Skin disorders that do not requires hormone replacement therapy